In the past, heparin has been the sole anticoagulant for interventional car
diovascular procedures. Today, several alternate approaches to anticoagulat
e patients with heparin-induced thrombocytopenia (HIT) are under considerat
ion. Antiplatelet drugs, such as the ADP receptor antagonists and inhibitor
s of glycoprotein (GP) IIb/IIIa, are currently in development. We investiga
ted the effect of two anti-platelet agents on platelet activation induced b
y HIT serum (n = 5 HIT positive sera, n = 5 HIT negative sera and n = 4 don
or platelets) and heparin, using the traditional platelet aggregation assay
, a Lumi-aggregation assay to also determine platelet release, and flow cyt
ometry. By all methods, the GIP IIb/IIIa inhibitor-GPI 562 (Novartis; Nurnb
erg, Germany)-produced a concentration dependent (6.25 to 125 ng/mL) decrea
se in platelet activation, as shown by platelet aggregation, platelet micro
particle formation, P-selectin expression, and ATP release. Similar results
were obtained with the thienopyridine ADP receptor antagonist ticlopidine
(Sanofi Recherche; Toulouse, France) in vitro at high concentrations of 5.0
to 50 mu g/mL and ex vivo in a patient dosed at 250 mg/day. These studies
show that GP IIb/IIIa and ADP receptor inhibitors can block platelet activa
tion induced by HIT serum/heparin, providing evidence that the mechanism of
HIT may be multifactorial involving not only the generation of the heparin
-PF4 or other antibodies but also involving platelet-specific processes and
, potentially, the generation of proaggregatory substances. The new antipla
telet agents may be useful in the clinical management of HIT patients.